Drug Class Review on Pharmacologic Treatments for ADHD: Final Report [Internet]

Marian S McDonagh; Kim Peterson; Tracy Dana; Sujata Thakurta

Drug Class Review on Pharmacologic Treatments for ADHD: Final Report [Internet]

Review

Portland (OR): Oregon Health & Science University; 2007 Dec.

Drug Class Reviews.

Authors

Marian S McDonagh¹, Kim Peterson¹, Tracy Dana¹, Sujata Thakurta¹

Affiliation

¹ Oregon Evidence-based Practice Center, Oregon Health & Science University, Mark Helfand, MD, MPH, Director

PMID: 20480923
Bookshelf ID: NBK10293

Excerpt

According to the most recent NIH Consensus Statement (1998), "attention deficit hyperactivity disorder (ADHD) is the most commonly diagnosed childhood behavioral disorder." Historically, drug therapy of ADHD has consisted primarily of stimulant medications. More recently, nonstimulant medication treatment alternatives have been identified. The purpose of this review is to compare the benefits and harms of different pharmacologic treatments for ADHD in children and adults.

Sections

Publication types

Review

Grants and funding

The funding source, the Center for Evidence-based Policy, is supported by 17 organizations, including 15 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.